Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Oncotarget | Effectiveness of radiotherapy for local control in T3N0 rectal cancer managed with total mesorectal excision: a meta-analysis

News

October 13, 2022
PRESS RELEASE: On October 8, 2022, a new research paper was published in Oncotarget, entitled, “Effectiveness of radiotherapy for local control in T3N0 rectal cancer managed with total mesorectal excision: a meta-analysis.” continue reading »

Oncotarget | In vitro chemotherapy-associated muscle toxicity is attenuated with nutritional support, while treatment efficacy is retained

News

October 11, 2022
PRESS RELEASE: A new Oncotarget research paper was published on October 8, 2022, entitled, “In vitro chemotherapy-associated muscle toxicity is attenuated with nutritional support, while treatment efficacy is retained.” continue reading »

CRISPR Screens Identify Novel Targets for Personalized Cancer Therapy

Oncotarget

October 7, 2022
In this trending new study, researchers used CRISPR-based genome-wide screens to identify genetic determinants of PARP10-mediated cellular survival. continue reading »

Oncotarget | Genomic alterations predictive of poor clinical outcomes in pan-cancer

News

October 4, 2022
PRESS RELEASE: A new research paper was published in Oncotarget's Volume 13 on September 28, 2022, entitled, “Genomic alterations predictive of poor clinical outcomes in pan-cancer.” continue reading »

Oncotarget | Site of analysis matters – Ongoing complete response to Nivolumab in a patient with HIV/HPV related metastatic anal cancer and MLH1 mutation

News

September 29, 2022
PRESS RELEASE: A new Oncotarget research paper was published, entitled, “Site of analysis matters - Ongoing complete response to Nivolumab in a patient with HIV/HPV related metastatic anal cancer and MLH1 mutation.” continue reading »